Global Dysautonomia Market, By Type (Neurocardiogenic Syncope, Postural Orthostatic Tachycardia Syndrome, Multiple System Atrophy, Autonomic Dysreflexia, Baroreflex Failure, Diabetic Autonomic Neuropathy, Familial Dysautonomia), Treatment (Physical Therapy, Counselling), Route of Administration (Parenteral, Others), End-Users (Veterinary Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Dysautonomia Market Analysis and Size
Increasing dysautonomia occurrence among the aging population worldwide is the key growth driver for the dysautonomia market. Increasing research and development undertakings to produce improved drugs and approval of these drugs by several authorities for the treatment of dysautonomia could also boost the overall dysautonomia market. Several growth strategies such as novel product launches could help the market players gain a competitive edge over others.
Data Bridge Market Research analyses a growth rate in the dysautonomia market in the forecast period 2023-2030. The expected CAGR of dysautonomia market is tend to be around 12% in the mentioned forecast period. The market was valued at USD 2708.03 million in 2022, and it would grow upto USD 6705 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Dysautonomia Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Neurocardiogenic Syncope, Postural Orthostatic Tachycardia Syndrome, Multiple System Atrophy, Autonomic Dysreflexia, Baroreflex Failure, Diabetic Autonomic Neuropathy, Familial Dysautonomia), Treatment (Physical Therapy, Counselling), Route of Administration (Parenteral, Others), End-Users (Veterinary Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Novartis AG (Switzerland), Axsome Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), H. Lundbeck A/S (Denmark), Celltex Therapeutics Corporation (U.S.), Theravance Biopharma (U.S.), SANTHERA PHARMACEUTICALS (Switzerland), Merck & Co., Inc. (U.S.)
|
|
Market Opportunities
|
|
Market Definition
Dysautonomia is the type of medical condition affecting the autonomic nervous systemaffecting the autonomic nervous system responsible for regulating breathing, controlling the internal temperature, and blood pressure level and moderating the heart rate. This condition occurs when the nerves in ANS are not able to communicate, send or receive messages as the normal neurological functions of the body. The symptoms is different from patient-to-patient.
Dysautonomia Market Dynamics
Drivers
- Increasing Awareness and Strategic Collaborations
The key market players in the dysautonomia market are projected to account for a large share in future. Several growth strategies such as novel product launches could help well-established market players gain a competitive edge over others. Multiple collaborations with smaller players could help the market players to expand their market presence and increase their revenue shares. A lot of awareness regarding the disease is also well established. Lately, Dysautonomia Foundation released a set of videos that provides more information on familial dysautonomia and spreads awareness about their work to help the community suffering from the disorder.
Opportunities
- Growing Incidence of Diabetes
The number of people who are suffering from diabetes increases from 108 million in 1980 to 422 million in 2014. Prevalence has increased rapidly in low and middle-income countries than the high-income countries. There was a 3% increase in diabetes mortality rates by age between 2000 and 2019. In 2019, diabetes and kidney disease caused around 2 million deaths. Abundant studies have shown that zinc improves glucose levels in people suffering from diabetes. This leads to the market growth.
Restraints/Challenges
- High Cost of Treatment
The enormous expenditure associated with the treatment of dysautonomia impede the market growth. The treatment becomes quite unaffordable in middle-income countries, thus, in a way limiting the market growth.
This dysautonomia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the dysautonomia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth
Global Dysautonomia Market Scope
The dysautonomia market is segmented on the basis of type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Neurocardiogenic Syncope
- Postural Orthostatic Tachycardia Syndrome
- Multiple System Atrophy
- Autonomic Dysreflexia, Baroreflex Failure
- Diabetic Autonomic Neuropathy
- Familial Dysautonomia
Treatment
- Physical Therapy
- Counselling
Route of Administration
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Dysautonomia Market Regional Analysis/Insights
The dysautonomia market is analyzed and market size insights and trends are provided by type, treatment, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the dysautonomia market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for dysautonomia market throughout the forecasted period due to increased government support for the effective drugs available and rising awareness about the chronic nature of dysautonomia disorders among the people
North America dominates the market due to the presence of key manufacturers of the product and availability of advanced technological treatment within the market.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Dysautonomia Market Share Analysis
The dysautonomia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to dysautonomia market.
Key players operating in the dysautonomia market include:
- Novartis AG (Switzerland)
- Axsome Therapeutics, Inc. (U.S.)
- Pfizer Inc. (U.S.)
- H. Lundbeck A/S (Denmark)
- Celltex Therapeutics Corporation (U.S.)
- Theravance Biopharma (U.S.)
- SANTHERA PHARMACEUTICALS (Switzerland)
- Merck & Co., Inc. (U.S.)
SKU-